Biolinerx Ltd (BLRX) 1.01 $BLRX
BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
PR Newswire - 2 mins ago
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer Company of Ben-Gurion University, and Hadasit, the Technology Transfer Company of Hadassah Medical Organization, for the in-licensing of a novel treatment for various liver failure conditions such as end-stage liver disease (ESLD) and for conditions potentially leading to liver failure such as non-alcoholic steatohepatitis (NASH). This novel treatment, to be named BL-1220, is the second project in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.
BLRX: 1.01 (-0.01)
BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY
PR Newswire - Thu Sep 22, 8:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today its corporate objectives at an ongoing investor breakfast meeting at the Convene Conference Center near Grand Central in New York City. These objectives include continued execution of advanced clinical studies for its lead oncology platform, deepening of its existing strategic collaborations with leading global pharma companies, focused pipeline development into additional high-value markets, and targeted milestones in line with its five-year corporate vision.
BLRX: 1.01 (-0.01)
BioLineRx Begins Trial on BL-8040/ Keytruda Combination
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 10:17AM CDT
BioLineRx, Ltd. (BLRX) announced the initiation of a phase IIa trial on its lead oncology candidate, BL-8040, in combination with Merck & Co., Inc.???s (MRK) lung cancer drug Keytruda (pembrolizumab).
MRK: 63.02 (+0.32), BLRX: 1.01 (-0.01)
BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
PR Newswire - Tue Sep 20, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX) today announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer.
BLRX: 1.01 (-0.01)
BioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New York
PR Newswire - Fri Sep 09, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE : BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will host an investor breakfast meeting on Thursday, September 22, 2016 at the Convene Conference Center near Grand Central in New York, NY.
BLRX: 1.01 (-0.01)
BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference
PR Newswire - Thu Sep 08, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced that the successful final results of BL-8040's Phase 2a clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML) were presented yesterday evening at the 4th Annual Meeting of the Society of Hematologic Oncology (SOHO), being held September 7-10, 2016, in Houston, Texas.
BLRX: 1.01 (-0.01)
BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
PR Newswire - Wed Sep 07, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors.
BLRX: 1.01 (-0.01)
BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York
PR Newswire - Mon Aug 29, 6:00AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace Hotel in New York City.
BLRX: 1.01 (-0.01)
BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China
PR Newswire - Thu Aug 25, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets.
BLRX: 1.01 (-0.01)
BioLineRx Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 11, 6:15AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the second quarter ended June 30, 2016.
BLRX: 1.01 (-0.01)
BioLineRx Names Philip A. Serlin as Chief Executive Officer
PR Newswire - Thu Aug 11, 5:45AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016.
VBLT: 4.86 (+0.11), BLRX: 1.01 (-0.01)
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
PR Newswire - Mon Aug 08, 6:00AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the signing of a collaboration agreement with The University of Texas MD Anderson Cancer Center for the investigation of BL-8040 in combination with KEYTRUDA® (pembrolizumab) in pancreatic cancer. The study will be conducted as an investigator-sponsored study, as part of a strategic clinical research collaboration between MSD (known as Merck in the US and Canada) and MD Anderson Cancer Center aimed at evaluating Merck's anti-PD-1 therapy, KEYTRUDA, in combination with various treatments and novel drugs.
MRK: 63.02 (+0.32), BLRX: 1.01 (-0.01)
BioLineRx to Report Second Quarter Results on August 11, 2016
PR Newswire - Thu Aug 04, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended June 30, 2016, on Thursday, August 11, 2016, before the U.S. markets open.
BLRX: 1.01 (-0.01)
BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration
PR Newswire - Mon Aug 01, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed an exclusive worldwide agreement with Hadasit, the Technology Transfer Company of Hadassah Medical Organization, for the in-licensing of a drug candidate for the treatment of liver fibrosis, and in particular, non-alcoholic steatohepatitis (NASH). This drug candidate, to be called BL-1210, is the first project to be in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.
BLRX: 1.01 (-0.01)
BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences
PR Newswire - Thu May 19, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences.
BLRX: 1.01 (-0.01)
BioLineRx Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 17, 7:04AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2016.
BLRX: 1.01 (-0.01)
BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement
PR Newswire - Mon May 16, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for fifteen of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of startup companies originating from MaRS Innovation's members, in order to identify in-licensing, co-development or other partnering opportunities.
BLRX: 1.01 (-0.01)
BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
PR Newswire - Tue Apr 19, 7:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that detailed results from a study on the underlying mechanism of action of BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, were presented by Prof. Amnon Peled at the American Association of Cancer Research (AACR) 2016 meeting in New Orleans.
BLRX: 1.01 (-0.01)
BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
PR Newswire - Mon Jan 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the European Notified Body regarding the classification of BL-7010, a novel polymer for the treatment of celiac disease, as a Class IIb medical device in the European Union.
BLRX: 1.01 (-0.01)
BioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco
PR Newswire - Mon Jan 04, 6:00AM CST
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA.
BLRX: 1.01 (-0.01)
BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
PR Newswire - 2 mins ago
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer Company of Ben-Gurion University, and Hadasit, the Technology Transfer Company of Hadassah Medical Organization, for the in-licensing of a novel treatment for various liver failure conditions such as end-stage liver disease (ESLD) and for conditions potentially leading to liver failure such as non-alcoholic steatohepatitis (NASH). This novel treatment, to be named BL-1220, is the second project in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.
BLRX: 1.01 (-0.01)
BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY
PR Newswire - Thu Sep 22, 8:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today its corporate objectives at an ongoing investor breakfast meeting at the Convene Conference Center near Grand Central in New York City. These objectives include continued execution of advanced clinical studies for its lead oncology platform, deepening of its existing strategic collaborations with leading global pharma companies, focused pipeline development into additional high-value markets, and targeted milestones in line with its five-year corporate vision.
BLRX: 1.01 (-0.01)
BioLineRx Begins Trial on BL-8040/ Keytruda Combination
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 10:17AM CDT
BioLineRx, Ltd. (BLRX) announced the initiation of a phase IIa trial on its lead oncology candidate, BL-8040, in combination with Merck & Co., Inc.???s (MRK) lung cancer drug Keytruda (pembrolizumab).
MRK: 63.02 (+0.32), BLRX: 1.01 (-0.01)
BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
PR Newswire - Tue Sep 20, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX) today announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer.
BLRX: 1.01 (-0.01)
BioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New York
PR Newswire - Fri Sep 09, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE : BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will host an investor breakfast meeting on Thursday, September 22, 2016 at the Convene Conference Center near Grand Central in New York, NY.
BLRX: 1.01 (-0.01)
BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference
PR Newswire - Thu Sep 08, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced that the successful final results of BL-8040's Phase 2a clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML) were presented yesterday evening at the 4th Annual Meeting of the Society of Hematologic Oncology (SOHO), being held September 7-10, 2016, in Houston, Texas.
BLRX: 1.01 (-0.01)
BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
PR Newswire - Wed Sep 07, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors.
BLRX: 1.01 (-0.01)
BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York
PR Newswire - Mon Aug 29, 6:00AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace Hotel in New York City.
BLRX: 1.01 (-0.01)
BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China
PR Newswire - Thu Aug 25, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets.
BLRX: 1.01 (-0.01)
BioLineRx Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 11, 6:15AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the second quarter ended June 30, 2016.
BLRX: 1.01 (-0.01)
BioLineRx Names Philip A. Serlin as Chief Executive Officer
PR Newswire - Thu Aug 11, 5:45AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016.
VBLT: 4.86 (+0.11), BLRX: 1.01 (-0.01)
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
PR Newswire - Mon Aug 08, 6:00AM CDT
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the signing of a collaboration agreement with The University of Texas MD Anderson Cancer Center for the investigation of BL-8040 in combination with KEYTRUDA® (pembrolizumab) in pancreatic cancer. The study will be conducted as an investigator-sponsored study, as part of a strategic clinical research collaboration between MSD (known as Merck in the US and Canada) and MD Anderson Cancer Center aimed at evaluating Merck's anti-PD-1 therapy, KEYTRUDA, in combination with various treatments and novel drugs.
MRK: 63.02 (+0.32), BLRX: 1.01 (-0.01)
BioLineRx to Report Second Quarter Results on August 11, 2016
PR Newswire - Thu Aug 04, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended June 30, 2016, on Thursday, August 11, 2016, before the U.S. markets open.
BLRX: 1.01 (-0.01)
BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration
PR Newswire - Mon Aug 01, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed an exclusive worldwide agreement with Hadasit, the Technology Transfer Company of Hadassah Medical Organization, for the in-licensing of a drug candidate for the treatment of liver fibrosis, and in particular, non-alcoholic steatohepatitis (NASH). This drug candidate, to be called BL-1210, is the first project to be in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.
BLRX: 1.01 (-0.01)
BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences
PR Newswire - Thu May 19, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences.
BLRX: 1.01 (-0.01)
BioLineRx Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 17, 7:04AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2016.
BLRX: 1.01 (-0.01)
BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement
PR Newswire - Mon May 16, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for fifteen of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of startup companies originating from MaRS Innovation's members, in order to identify in-licensing, co-development or other partnering opportunities.
BLRX: 1.01 (-0.01)
BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
PR Newswire - Tue Apr 19, 7:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that detailed results from a study on the underlying mechanism of action of BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, were presented by Prof. Amnon Peled at the American Association of Cancer Research (AACR) 2016 meeting in New Orleans.
BLRX: 1.01 (-0.01)
BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
PR Newswire - Mon Jan 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the European Notified Body regarding the classification of BL-7010, a novel polymer for the treatment of celiac disease, as a Class IIb medical device in the European Union.
BLRX: 1.01 (-0.01)
BioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco
PR Newswire - Mon Jan 04, 6:00AM CST
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA.
BLRX: 1.01 (-0.01)
